Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001104659-25-036339
Filing Date
2025-04-18
Accepted
2025-04-18 16:01:26
Documents
16
Period of Report
2025-06-12

Document Format Files

Seq Description Document Type Size
1 DEF 14A tm252436-4_def14a.htm   iXBRL DEF 14A 630128
4 GRAPHIC lg_blackdiamond-4c.jpg GRAPHIC 13720
5 GRAPHIC px_blackdiamond2025pg01-bw.jpg GRAPHIC 215654
6 GRAPHIC px_blackdiamond2025pg02-bw.jpg GRAPHIC 208842
  Complete submission text file 0001104659-25-036339.txt   2045283

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA bdtx-20241231.xsd EX-101.SCH 9048
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE bdtx-20241231_lab.xml EX-101.LAB 33989
18 EXTRACTED XBRL INSTANCE DOCUMENT tm252436-4_def14a_htm.xml XML 7782
Mailing Address ONE MAIN STREET, 14TH FLOOR CAMBRIDGE MA 02142
Business Address ONE MAIN STREET, 14TH FLOOR CAMBRIDGE MA 02142 617-417-5868
Black Diamond Therapeutics, Inc. (Filer) CIK: 0001701541 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-39200 | Film No.: 25850450
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)